Menu Search
Equities

Abivax SA

2X1:DUS

Abivax SA

Actions
  • Price (EUR)9.45
  • Today's Change0.13 / 1.39%
  • Shares traded30.00
  • 1 Year change-2.28%
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024 07:11 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.

  • Revenue in EUR (TTM)0.00
  • Net income in EUR-177.43m
  • Incorporated2013
  • Employees62.00
  • Location
    Abivax SA7-11 Boulevard HaussmannPARIS 75009FranceFRA
  • Phone+33 153830963
  • Fax+33 494279261
  • Websitehttps://www.abivax.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.